Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in ...

REGN Quantitative Stock Analysis - Benjamin Graham December 30, 2023 — 09:00 am EST Written by John Reese for Validea -> ...

See why I no longer see REGN stock price upside in the near term. Skip to content. ... analysis I set a price target for the stock price of ~$815 - a 10% premium to Regeneron's share price today.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it’s free.

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. ... See our analysis on Regeneron Stock Chances of A Rise for more details.

At levels of $515, REGN stock is trading at 14x its 2021 estimated adjusted earnings of $36.81, compared to levels of 16x seen in 2018 and over 15x seen as recently as late 2019, implying the ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.